Literature DB >> 31541338

Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.

Cuiling Zhou1, Gang Che1, Xiaobin Zheng2, Junlan Qiu3, Zhinan Xie4, Yunyan Cong1, Xiaofeng Pei1, Hongyu Zhang1, Huanhuan Sun5, Haiqing Ma6.   

Abstract

BACKGROUND: It is known that there are insufficient prognostic factors for non-small cell lung cancer (NSCLC). It was reported that PD-L1 was a prognostic factor for NSCLC,and c-Myc regulated the expression of PD-L1. Herein, we investigated c-Myc and PD-L1 expression and their association with overall survival (OS) in NSCLC.
METHODS: Formalin-fixed paraffin-embedded specimens were obtained from 128 patients with surgically resected primary NSCLC. Immunohistochemistry was used to assess the expression of PD-L1 and c-Myc in this study. Pearson's Chi squared test or Fisher's exact test was used to analyze the correlation of the expression of PD-L1 and c-Myc with clinicopathologic features. The relationship between OS and the expression of PD-L1 and c-Myc was evaluated by the Kaplan-Meier method and Cox proportional hazards model, respectively.
RESULTS: Positive expression of PD-L1 was detected in 59 patients (46.1%). Patients with negative expression of PD-L1 had remarkably longer OS than those with positive expression of PD-L1. The positive expression rate of c-Myc in NSCLC accounted for 58.6% (75/128) and its expression was significantly more frequent in males (p = 0.002) and patients with lymph node metastasis (p = 0.029). PD-L1 expression was positively correlated with c-Myc expression (r = 0.459, p < 0.001). The PD-L1 and c-Myc double-positive group had a worse prognosis than other subgroups (p < 0.05), and the PD-L1 and c-Myc double-negative group had a better OS than other subgroups (p < 0.05).
CONCLUSION: Conjoint analysis of the expression of PD-L1 and c-Myc was a better prognostic approach for NSCLC patients.

Entities:  

Keywords:  Non-small cell lung cancer; Prognosis; Programmed cell death ligand 1; c-Myc

Mesh:

Substances:

Year:  2019        PMID: 31541338     DOI: 10.1007/s00432-019-03025-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.

Authors:  Y H Kim; L Girard; C P Giacomini; P Wang; T Hernandez-Boussard; R Tibshirani; J D Minna; J R Pollack
Journal:  Oncogene       Date:  2006-01-05       Impact factor: 9.867

Review 2.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

Review 3.  The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis.

Authors:  A Wang; H Y Wang; Y Liu; M C Zhao; H J Zhang; Z Y Lu; Y C Fang; X F Chen; G T Liu
Journal:  Eur J Surg Oncol       Date:  2015-01-31       Impact factor: 4.424

4.  PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.

Authors:  Ombretta Melaiu; Marco Mina; Marco Chierici; Renata Boldrini; Giuseppe Jurman; Paolo Romania; Valerio D'Alicandro; Maria C Benedetti; Aurora Castellano; Tao Liu; Cesare Furlanello; Franco Locatelli; Doriana Fruci
Journal:  Clin Cancer Res       Date:  2017-03-07       Impact factor: 12.531

5.  Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

Authors:  Takeo Nomi; Masayuki Sho; Takahiro Akahori; Kaoru Hamada; Atsushi Kubo; Hiromichi Kanehiro; Shinji Nakamura; Koji Enomoto; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

6.  PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Authors:  Wendy A Cooper; Thang Tran; Ricardo E Vilain; Jason Madore; Christina I Selinger; Maija Kohonen-Corish; PoYee Yip; Bing Yu; Sandra A O'Toole; Brian C McCaughan; Jennifer H Yearley; Lisa G Horvath; Steven Kao; Michael Boyer; Richard A Scolyer
Journal:  Lung Cancer       Date:  2015-05-18       Impact factor: 5.705

7.  MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis.

Authors:  Reika Iwakawa; Takashi Kohno; Motohiro Kato; Kouya Shiraishi; Koji Tsuta; Masayuki Noguchi; Seishi Ogawa; Jun Yokota
Journal:  Clin Cancer Res       Date:  2010-12-10       Impact factor: 12.531

Review 8.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.

Authors:  Arianna Sabò; Theresia R Kress; Mattia Pelizzola; Stefano de Pretis; Marcin M Gorski; Alessandra Tesi; Marco J Morelli; Pranami Bora; Mirko Doni; Alessandro Verrecchia; Claudia Tonelli; Giovanni Fagà; Valerio Bianchi; Alberto Ronchi; Diana Low; Heiko Müller; Ernesto Guccione; Stefano Campaner; Bruno Amati
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962

View more
  7 in total

1.  Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy.

Authors:  Ming Zhao; Jing Zhang; Siyu Chen; Yuqi Wang; Qing Tian
Journal:  Cancer Manag Res       Date:  2020-08-04       Impact factor: 3.989

2.  PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.

Authors:  Xiaodong Wu; Yan Huang; Qingping Zhao; Lei Wang; Xiao Song; Yi Li; Lei Jiang
Journal:  EJNMMI Res       Date:  2020-05-19       Impact factor: 3.138

3.  LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape.

Authors:  Zhoumiao Chen; Zhao Chen; Shaohua Xu; Qiang Zhang
Journal:  Front Genet       Date:  2021-07-30       Impact factor: 4.599

4.  Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.

Authors:  Yasuhito Mihashi; Shoichi Kimura; Hiromi Iwasaki; Yumi Oshiro; Yasushi Takamatsu; Shigeto Kawauchi; Shohei Shimajiri; Kenji Ishizuka; Morishige Takeshita
Journal:  Diagn Pathol       Date:  2021-11-06       Impact factor: 2.644

Review 5.  Epstein-Barr Virus Infection in Lung Cancer: Insights and Perspectives.

Authors:  Julio C Osorio; Rancés Blanco; Alejandro H Corvalán; Juan P Muñoz; Gloria M Calaf; Francisco Aguayo
Journal:  Pathogens       Date:  2022-01-21

6.  Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.

Authors:  Patrapim Sunpaweravong; Patcharaporn Thongwatchara; Rassamee Chotipanvithayakul; Surasak Sangkhathat; Paramee Thongsuksai
Journal:  Clin Med Insights Oncol       Date:  2022-04-22

7.  c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer.

Authors:  Jingjing Yao; Min Huang; Qinghong Shen; Ming Ding; Shaofang Yu; Yajuan Guo; Yuefang Lin; Yaqiu Zheng; Wenbo Chen; Wenxin Yan; Zhongqiu Liu; Dawei Wang; Ming Hu; Linlin Lu
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.